InnoPharmax Inc. (TPEX:4172)
Taiwan
· Delayed Price · Currency is TWD 15.45
+0.15 (0.98%)
Apr 25, 2025, 2:00 PM CST
InnoPharmax Revenue
In the year 2024, InnoPharmax had annual revenue of 32.30M TWD, down -29.90%. InnoPharmax had revenue of 9.13M in the half year ending December 31, 2024, a decrease of -36.79%.
Revenue
32.30M
Revenue Growth
-29.90%
P/S Ratio
52.29
Revenue / Employee
949.91K
Employees
34
Market Cap
1.69B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 32.30M | -13.78M | -29.90% |
| Dec 31, 2023 | 46.07M | 16.94M | 58.15% |
| Dec 31, 2022 | 29.13M | -18.93M | -39.38% |
| Dec 31, 2021 | 48.06M | -88.82M | -64.89% |
| Dec 31, 2020 | 136.88M | 51.99M | 61.24% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 9.73B |
| Caliway Biopharmaceuticals | 44.43M |
| Bora Pharmaceuticals Co., LTD. | 19.25B |
| Lotus Pharmaceutical | 18.58B |
| Oneness Biotech | 117.93M |
| Polaris Group | 107.00M |
| Lumosa Therapeutics | 39.15M |
| Pegavision | 6.82B |